文献速递消化道肿瘤放疗

直肠癌术前放化疗及其对结局的影响:一项基于人群的研究

Preoperative chemoradiotherapy for rectal cancer and impact on outcomes - A population-based study.
PubMed 文献 · Radiother Oncol · 2017-05-05

该研究利用挪威结直肠癌登记数据,纳入1997-2011年接受根治性手术的I-III期直肠癌患者9193例,分析术前放化疗使用趋势及结局。结果显示术前放化疗比例从5%升至49%,与局部复发风险降低相关(HR=0.55),并可能改善生存(excess HR=0.75),在≥70岁患者中效应显著。

要点

  • 挪威术前放化疗限于cT4或环周切缘受威胁的高危直肠癌患者。
  • 1997-2011年间术前放化疗使用比例从5%增至49%。
  • 术前放化疗与局部复发风险降低相关(HR=0.55),≥70岁患者效应显著。

核心结论

  • 在基于人群水平上,将术前放化疗限制于选定高危直肠癌时,其与局部复发改善相关,并可能改善生存。

研究设计与样本

  • 基于挪威结直肠癌登记数据的全国性人群研究,纳入1997-2011年接受根治性手术的I-III期直肠癌患者9193例。
  • 采用多变量回归模型比较术前放化疗联合手术与单纯手术的结局。

主要发现

  • 术前放化疗比例从1997年的5%增至2011年的49%。
  • 术前放化疗与局部复发风险降低相关(HR=0.55;95%CI=0.29-1.04)。
  • 术前放化疗与生存改善趋势相关(excess HR=0.75;95%CI=0.52-1.08)。
  • 在≥70岁患者中,术前放化疗与局部复发风险降低(HR=0.35;95%CI=0.13-0.91)及生存改善(excess HR=0.58;95%CI=0.35-0.95)显著相关。

临床怎么用

  • 对于cT4期或环周切缘受威胁的高危直肠癌患者,可考虑术前放化疗以改善局部控制。
  • 在老年(≥70岁)高危患者中,术前放化疗的局部复发和生存获益更为显著。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: Preoperative (chemo)radiotherapy ((C)RT) for rectal cancer is, in Norway, restricted to patients with cT4-stage or threatened circumferential resection margin. This nationwide population-based study assessed the use of preoperative (C)RT in Norway and its impact on treatment outcomes. PATIENTS AND METHODS: Data from The Norwegian Colorectal Cancer Registry were used to identify all stage I-III rectal cancers treated with major resection (1997-2011: n=9193). Cumulative risk of local recurrence, distant metastasis, and relative survival was estimated for patients in 2007-2011 (n=3179). Multivariate regression-models were used to compare outcomes following preoperative (C)RT and surgery versus surgery alone. RESULTS: The proportion of patients given preoperative (C)RT increased from 5% to 49% during 1997-2011. Preoperative (C)RT was associated with reduced risk of local recurrence (hazard ratio (HR)=0.55; 95% CI=0.29-1.04) and a tendency of improved survival (excess HR=0.75; 95% CI=0.52-1.08) with significant effects in patients aged ≥70years (local recurrence: HR=0.35; 95% CI=0.13-0.91; survival: excess HR=0.58; 95% CI=0.35-0.95). CONCLUSIONS: This study indicates that when use of preoperative (C)RT is restricted to selected high-risk rectal cancers, preoperative (C)RT is associated with improved local recurrence, and possibly improved survival, when studied on a population-based level.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Åsli LM, Johannesen TB, Myklebust TÅ, et al. Preoperative chemoradiotherapy for rectal cancer and impact on outcomes - A population-based study. Radiother Oncol. 2017. PMID: 28483302. doi:10.1016/j.radonc.2017.04.012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。